Q4 Earnings Estimate for Cooper Companies Issued By KeyCorp

Posted by Stanley Muller on Sep 23rd, 2026

The Cooper Companies, Inc. (NASDAQ:COO – Free Report) – Stock analysts at KeyCorp reduced their Q4 2026 earnings per share (EPS) estimates for shares of Cooper Companies in a report issued on Wednesday, September 9th. KeyCorp analyst B. Fishbin now forecasts that the medical device company will post earnings per share of $1.06 for the quarter, down from their prior forecast of $1.21. KeyCorp has a “Sector Weight” rating on the stock. The consensus estimate for Cooper Companies’ current full-year earnings is $4.53 per share.

Several other brokerages also recently issued reports on COO. Robert W. Baird set a $61.00 target price on shares of Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday, September 10th. Zacks Research downgraded shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research report on Friday, September 11th. William Blair lowered shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday, September 10th. Stifel Nicolaus set a $70.00 price objective on Cooper Companies and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Piper Sandler downgraded Cooper Companies from an “overweight” rating to a “neutral” rating and cut their target price for the company from $86.00 to $59.00 in a research note on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Cooper Companies presently has an average rating of “Hold” and an average target price of $71.47.

Check Out Our Latest Report on COO

Cooper Companies Stock Up 2.2%

NASDAQ:COO opened at $55.29 on Monday. The firm has a market cap of $10.51 billion, a P/E ratio of 18.87, a P/E/G ratio of 2.20 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The firm has a 50-day simple moving average of $69.32 and a two-hundred day simple moving average of $68.18.

Cooper Companies (NASDAQ:COO – Get Free Report) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.Cooper Companies’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS.

Cooper Companies announced that its board has authorized a share buyback plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Lawrence Kurzius acquired 10,000 shares of the stock in a transaction dated Wednesday, September 16th. The shares were purchased at an average price of $54.93 per share, for a total transaction of $549,300.00. Following the purchase, the director directly owned 31,099 shares of the company’s stock, valued at approximately $1,708,268.07. This trade represents a 47.40% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Walter M. Rosebrough, Jr. acquired 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was acquired at an average cost of $54.29 per share, for a total transaction of $162,870.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,085,800. The trade was a 17.65% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 34,701 shares of company stock worth $1,880,039. 2.08% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Root Financial Partners LLC grew its stake in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after buying an additional 162 shares during the last quarter. Essential Partners LLC raised its stake in shares of Cooper Companies by 23.4% in the first quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock valued at $62,000 after acquiring an additional 166 shares during the last quarter. Allworth Financial LP raised its stake in shares of Cooper Companies by 14.1% in the fourth quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock valued at $111,000 after acquiring an additional 167 shares during the last quarter. SJS Investment Consulting Inc. boosted its holdings in shares of Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after acquiring an additional 187 shares in the last quarter. Finally, Nicolet Advisory Services LLC boosted its holdings in shares of Cooper Companies by 7.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,291 shares of the medical device company’s stock worth $274,000 after acquiring an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: Activist pressure could ultimately unlock shareholder value if Cooper agrees to divest noncore products or businesses, improves capital allocation and replaces senior leadership. However, these potential benefits depend on the company taking action. Investor trust has been broken: Activist pushes Cooper Cos. to divest products, ditch CEO
Neutral Sentiment: KeyCorp issued a fourth-quarter earnings forecast for Cooper Companies. The update may provide investors with an additional view of near-term results, although the available report does not identify a material change to company guidance. Q4 Earnings Forecast for Cooper Companies Issued By KeyCorp
Negative Sentiment: Activist investor Eric Schoenberg is urging Cooper to replace CEO Albert White III and sell or separate certain assets, arguing that the company has underperformed and that investor trust has deteriorated. The campaign increases governance uncertainty and could distract management. Cooper Companies continues to see activist pressure to sell divisions, replace CEO
Negative Sentiment: Cooper ended its strategic review of CooperSurgical after determining that submitted bids were not in shareholders’ interests. Keeping the unit avoids selling at an unattractive price, but removes a potential near-term catalyst and suggests the review failed to generate sufficient value. A Failed Auction and a 15% Drop: Is Cooper Companies a Value Trap or a Bargain?
Negative Sentiment: Pomerantz and Rosen Law Firm have announced investigations into potential securities claims, including allegations that Cooper may have issued materially misleading business information. These announcements do not establish wrongdoing, but they add litigation risk, reputational pressure and uncertainty for shareholders. Pomerantz investor alert Rosen Law Firm investigation

Cooper Companies Company Profile

(Get Free Report)

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.